Ionis Pharmaceuticals (IONS) Panoramica del titolo
Ionis Pharmaceuticals, Inc. è una società di biotecnologie in fase di sviluppo commerciale e fornisce farmaci mirati all'RNA negli Stati Uniti. Maggiori dettagli
| Punteggio fiocco di neve | |
|---|---|
| Valutazione | 3/6 |
| Crescita futura | 6/6 |
| Prestazioni passate | 0/6 |
| Salute finanziaria | 4/6 |
| Dividendi | 0/6 |
Premi
Analisi del rischio
Non sono stati rilevati rischi per IONS dai nostri controlli di rischio.
IONS Community Fair Values
Create NarrativeSee what 25 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Concorrenti di Ionis Pharmaceuticals, Inc.
Storia dei prezzi e prestazioni
| Prezzi storici delle azioni | |
|---|---|
| Prezzo attuale dell'azione | US$60.80 |
| Massimo di 52 settimane | US$86.74 |
| Minimo di 52 settimane | US$41.71 |
| Beta | 0.40 |
| Variazione di 1 mese | 14.83% |
| Variazione a 3 mesi | -19.77% |
| Variazione di 1 anno | 42.02% |
| Variazione a 3 anni | 53.07% |
| Variazione a 5 anni | 53.77% |
| Variazione dall'IPO | 508.00% |
Notizie e aggiornamenti recenti
Recent updates
Aggiornamento narrativa • Aug 06
IONS: sHTG Launch And Late Stage Pipeline Will Support Future Earnings Power
Ionis Pharmaceuticals' updated analyst price target is now $114.18, with analysts pointing to revised expectations for higher revenue growth and profit margins, offset by a lower future P/E assumption and a slightly higher discount rate, following recent mixed trial outcomes and ongoing enthusiasm around the Tryngolza and sHTG opportunity. Analyst Commentary Recent Street research on Ionis Pharmaceuticals points to a split view.
Aggiornamento narrativa • Jul 23
IONS: Tryngolza Approval And Rare Disease Pipeline Will Reshape 2026 Risk Reward Profile
Ionis Pharmaceuticals' fair value estimate has been reset from $104.86 to $92.00, as analysts incorporate the Phase 3 eplontersen cardiomyopathy miss, related trims to revenue growth and profit margin assumptions, and a higher projected future P/E. These factors are all reflected in a wave of reduced price targets across the Street.Seeking Alpha • Jul 16
Ionis Pharmaceuticals: The Heartbreak Is Priced In
Summary The ATTR-CM and tominersen setbacks drove an excessive selloff without impairing Ionis’s wholly owned core assets. Tryngolza is the main value driver, supported by strong triglyceride and pancreatitis data and a large sHTG market. Dawnzera's upcoming pipeline catalysts and $1.9B of liquidity support growth and a credible path to 2028 breakeven. Despite reimbursement, competition, and execution risks, Ionis’s ~$9B valuation offers attractive upside, supporting a speculative BUY. Read the full article on Seeking AlphaAggiornamento narrativa • Jul 09
IONS: Severe Triglyceride Label Win Will Reshape 2026 Risk Reward Profile
Analysts have raised the Ionis Pharmaceuticals fair value estimate by about $3.94 to $104.86, citing updated price targets following the FDA approval of Tryngolza, as well as increased confidence in the company’s proprietary and partnered pipeline. Analyst Commentary Recent research on Ionis Pharmaceuticals clusters around the FDA approval of Tryngolza and its implications for valuation, execution risk and long term growth potential across the company’s proprietary and partnered pipeline.
Aggiornamento narrativa • Jun 25
IONS: FDA Approvals And 2026 Readouts Will Test Balanced Expectations
The analyst price target for Ionis Pharmaceuticals has been raised from $62.78 to $79.71, with analysts citing the FDA approval of Tryngolza and updated assumptions for revenue growth, profit margin, and future P/E as key drivers of the change. Analyst Commentary Recent Street research on Ionis Pharmaceuticals centers on the FDA approval of Tryngolza and how this new product feeds into long term revenue, margin, and P/E assumptions.Articolo di analisi • Jun 22
Ionis Pharmaceuticals (IONS) Stock Could Be 26.6% Undervalued After New Olezarsen Data
Ionis Pharmaceuticals (IONS) recently shared new long-term data on its RNA therapy olezarsen for severe hypertriglyceridemia, highlighting sustained effects on liver fat and a favorable safety profile in an ongoing extension study. See our latest analysis for Ionis Pharmaceuticals. Ionis Pharmaceuticals’ share price is US$74.12, with short term moves roughly flat as the 7 day share price return of 1.15% and 30 day share price return, down 1.91%, contrast with a much stronger 1 year total...Aggiornamento narrativa • Jun 11
IONS: Priority Review In Severe Triglycerides Will Drive 2026 Risk Reward Repricing
Analysts have lifted their average price target on Ionis Pharmaceuticals toward $115, reflecting renewed focus on the $3.5b-plus Tryngloza opportunity in severe hypertriglyceridemia and upcoming partnered Phase 3 readouts in 2026, while leaving the modeled fair value at about $100.92 as the discount rate and margin assumptions are fine tuned. Analyst Commentary Street research around Ionis Pharmaceuticals has centered on how much value to ascribe to Tryngloza and the broader pipeline, with recent work fine tuning price targets and risk assumptions rather than radically changing the fundamental narrative.Aggiornamento narrativa • May 28
IONS: Priority Review In Severe Triglycerides Will Reshape 2026 Risk Reward Profile
Ionis Pharmaceuticals' fair value estimate has moved from $96.73 to $100.92 as analysts factor in higher assumed revenue growth, a stronger profit margin profile, and a lower future P/E multiple, supported by a wave of higher price targets and fresh Buy initiations that highlight the potential of Tryngloza and upcoming partnered Phase 3 readouts. Analyst Commentary Recent Street research around Ionis Pharmaceuticals has been active, with multiple firms adjusting price targets and launching new coverage.Articolo di analisi • May 11
Need To Know: Analysts Are Much More Bullish On Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) Revenues
Shareholders in Ionis Pharmaceuticals, Inc. ( NASDAQ:IONS ) may be thrilled to learn that the analysts have just...Aggiornamento narrativa • May 02
IONS: Priority FDA Reviews In 2026 Will Support Stronger Earnings Power
Analysts have nudged the Ionis Pharmaceuticals fair value estimate higher to $130 from $120, citing a series of price target increases across the Street and updated assumptions around growth, profitability, and future P/E levels. Analyst Commentary Recent Street research around Ionis Pharmaceuticals has leaned constructive, with a cluster of bullish analysts lifting price targets and reinforcing a positive view on execution and long term growth potential, even as one firm trimmed its target.Articolo di analisi • May 01
Earnings Beat: Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) Just Beat Analyst Forecasts, And Analysts Have Been Lifting Their Forecasts
Ionis Pharmaceuticals, Inc. ( NASDAQ:IONS ) just released its first-quarter report and things are looking bullish. The...Aggiornamento narrativa • Apr 18
IONS: Priority Review For Severe Triglycerides Will Reframe 2026 Risk Reward Profile
Analysts have raised their fair value estimate for Ionis Pharmaceuticals by about $3 to $96.73, citing updated assumptions for higher revenue growth, a wider profit margin, and a lower future P/E multiple, along with a series of recent price target increases and positive ratings resets from major firms. Analyst Commentary Recent research updates on Ionis Pharmaceuticals have leaned constructive, with several firms lifting price targets and reiterating positive ratings following the latest quarterly results and pipeline updates.Aggiornamento narrativa • Apr 04
IONS: Priority FDA Reviews In 2026 Will Support Stronger Profitability Profile
Analysts have lifted the Ionis Pharmaceuticals fair value estimate by $3.24 to $120.00, as they factor in updated assumptions around revenue growth, profit margins, and future P/E multiples following recent price target increases across the Street. Analyst Commentary Bullish analysts have been lifting Ionis Pharmaceuticals price targets across several research updates, which feeds directly into the higher fair value estimate.Aggiornamento narrativa • Mar 20
IONS: Priority Review For Severe Triglycerides Will Shape 2026 Outlook
Ionis Pharmaceuticals' updated analyst price target moves higher to $93.90 from $90.67. Analysts point to recent target hikes, Q4 results commentary and upcoming 2026 catalysts as key supports for this shift.Aggiornamento narrativa • Mar 06
IONS: 2026 Regulatory Event Risk Will Test Elevated Expectations
Ionis Pharmaceuticals' fair value estimate has been raised from $43.00 to about $62.78 as analysts factor in higher long term revenue growth assumptions, updated margin expectations, and recent price target increases following Q4 results, olezarsen progress, and a busy 2026 catalyst calendar. Analyst Commentary Recent Street research on Ionis Pharmaceuticals points to a more constructive stance on the story overall, but there are still threads of caution that matter if you are thinking about risk, valuation, and execution over the next couple of years.Aggiornamento narrativa • Feb 19
IONS: Late-Stage RNA Programs Will Support Stronger Future Profitability Profile
Analysts have lifted their price target on Ionis Pharmaceuticals by $10, citing updated expectations around revenue growth, profit margins and a lower future P/E assumption, as reflected in recent research from firms covering the stock. Analyst Commentary Recent Street research points to a generally constructive tone on Ionis Pharmaceuticals, with bullish analysts highlighting both valuation and execution angles in their updated work.Aggiornamento narrativa • Feb 05
IONS: Triglyceride Market Shift And SHTG Launch Progress Will Shape Outlook
Analysts nudged their fair value target for Ionis Pharmaceuticals slightly higher to about US$90.67 from roughly US$90.63, citing updated assumptions around discount rates, revenue growth, profit margins and a higher future P/E, along with recent Street research that highlights evolving expectations for the triglyceride lowering market where Ionis and Arrowhead both participate. Analyst Commentary Bullish Takeaways Bullish analysts view the refreshed fair value near US$90.67 as consistent with a company that could justify a higher future P/E, reflecting confidence in execution rather than only near term trading sentiment.Aggiornamento narrativa • Jan 22
IONS: Upcoming SHTG Data And Launch Execution Will Support Bullish Thesis
Analysts have lifted their fair value estimate for Ionis Pharmaceuticals to about US$90.63 from roughly US$89.40, citing updated models that reflect recent Q3 performance, higher assumed revenue growth and profit margins, as well as a lower future P/E. This comes alongside Street price target increases to US$94 and US$99 following Tryngolza driven strength and expectations around upcoming SHTG data.Aggiornamento narrativa • Jan 08
IONS: Late-Stage Data And New Launches Will Shape Balanced Risk Profile
Analysts nudged their fair value estimate for Ionis Pharmaceuticals higher from about $85.95 to roughly $89.40. They pointed to updated models that reflect recent price target increases, added expectations for Tryngolza in FCS and severe hypertriglyceridemia, and revised long term margin and P/E assumptions.Aggiornamento narrativa • Dec 24
IONS: Late-Stage RNA Pipeline Will Drive Stronger Profitability Outlook
Analysts have raised their fair value estimate for Ionis Pharmaceuticals from approximately $96 to about $117 per share, citing strong Q3 outperformance led by Tryngolza, expanded peak sales assumptions for key lipid programs, and growing confidence in the late-stage pipeline and path to profitability. Analyst Commentary Bullish analysts are increasingly constructive on Ionis Pharmaceuticals following a series of positive catalysts, including strong Q3 performance from Tryngolza, encouraging late-stage data, and visible progress toward breakeven and long term profitability.Aggiornamento narrativa • Dec 10
IONS: Late-Stage Data And Multiple Launches Will Shape Balanced Long-Term Outlook
Analysts have modestly raised their fair value estimate for Ionis Pharmaceuticals to approximately $86 per share. This reflects higher peak sales assumptions for Tryngolza and other late stage programs, a slightly richer pricing outlook in severe hypertriglyceridemia, and growing confidence in the company reaching multi billion dollar revenue and profitability in the early 2030s.Aggiornamento narrativa • Nov 26
IONS: Upcoming Late-Stage Data and Recent Regulatory Progress Will Shape Balanced Outlook
Ionis Pharmaceuticals’ analyst price target has been raised from approximately $82 to $85 per share. This reflects analyst optimism following strong Phase 3 trial results, upward sales guidance, and an improved clinical and commercial outlook across multiple pipeline programs.Aggiornamento narrativa • Nov 05
IONS: Continued Clinical Success Will Drive Meaningful Upside After Recent Regulatory Wins
The consensus analyst price target for Ionis Pharmaceuticals has increased significantly, rising from approximately $77 to over $82. Analysts cite robust clinical trial results, new product milestones, and a strengthened commercial outlook as key drivers behind their upward revisions.Articolo di analisi • Nov 01
Earnings Update: Here's Why Analysts Just Lifted Their Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) Price Target To US$81.91
Ionis Pharmaceuticals, Inc. ( NASDAQ:IONS ) defied analyst predictions to release its third-quarter results, which were...Aggiornamento narrativa • Oct 22
Analyst Commentary Highlights Ionis Pharmaceuticals’ Upward Price Target and Valuation Amid Key Clinical Wins
Ionis Pharmaceuticals’ analyst price target has been raised from approximately $73 to $77. Analysts cite stronger-than-expected clinical and commercial progress across key late-stage programs, as well as expanded opportunities in rare disease markets.Aggiornamento narrativa • Oct 08
Pipeline Milestones And Expanding Patient Pools Will Broaden Market Reach
Ionis Pharmaceuticals’ analyst price target has been raised from approximately $69.48 to $73.03, as analysts cite strong Phase 3 results across multiple programs and expanded opportunities in ultra-rare indications, which support increased sales and profit expectations. Analyst Commentary Recent analyst updates on Ionis Pharmaceuticals reveal a nuanced outlook as the company benefits from significant clinical milestones and expanding commercial prospects, but also faces some areas of uncertainty.Aggiornamento narrativa • Sep 23
Pipeline Milestones And Expanding Patient Pools Will Broaden Market Reach
Analysts increased their price targets for Ionis Pharmaceuticals following "groundbreaking" Phase 3 data for olezarsen, blockbuster expectations, and a major regulatory win for Dawnzera, resulting in a modest consensus target rise from $68.35 to $69.48. Analyst Commentary Bullish analysts significantly raised price targets after Phase 3 trial data for olezarsen/Tryngolza in severe hypertriglyceridemia showed "groundbreaking" or "highly statistically significant" triglyceride reductions and, notably, the first proven benefit in reducing acute pancreatitis.Articolo di analisi • Sep 03
Ionis Pharmaceuticals, Inc.'s (NASDAQ:IONS) 34% Share Price Surge Not Quite Adding Up
Despite an already strong run, Ionis Pharmaceuticals, Inc. ( NASDAQ:IONS ) shares have been powering on, with a gain of...Aggiornamento narrativa • Aug 27
Pipeline Milestones And Expanding Patient Pools Will Broaden Market Reach
Ionis Pharmaceuticals’ consensus price target edged up to $59.19 as analysts cited favorable FDA approval and label for Dawnzera in hereditary angioedema, strong initial launches, and growing pipeline confidence as key drivers, outweighing modest concerns on Wainua revenues. Analyst Commentary FDA approval of Dawnzera with a favorable, broad label (including both every four and eight week dosing) and absence of major safety warnings, positioning it competitively against Takhzyro and Andembry in hereditary angioedema.Rendimenti per gli azionisti
| IONS | US Biotechs | US Mercato | |
|---|---|---|---|
| 7D | 7.6% | 6.2% | -0.8% |
| 1Y | 42.0% | 46.3% | 20.5% |
Ritorno vs Industria: IONS ha superato il US Biotechs che ha restituito 46.3 % nell'ultimo anno.
Rendimento vs Mercato: IONS ha superato il mercato US che ha restituito 20.5 % nell'ultimo anno.
Volatilità dei prezzi
| IONS volatility | |
|---|---|
| IONS Average Weekly Movement | 8.5% |
| Biotechs Industry Average Movement | 9.9% |
| Market Average Movement | 7.2% |
| 10% most volatile stocks in US Market | 16.4% |
| 10% least volatile stocks in US Market | 3.1% |
Prezzo delle azioni stabile: IONS non ha avuto una volatilità dei prezzi significativa negli ultimi 3 mesi rispetto al mercato US.
Volatilità nel tempo: La volatilità settimanale ( 8% ) di IONS è rimasta stabile nell'ultimo anno.
Informazioni sull'azienda
| Fondato | I dipendenti | AMMINISTRATORE DELEGATO | Sito web |
|---|---|---|---|
| 1989 | 1,480 | Brett Monia | www.ionis.com |
Ionis Pharmaceuticals, Inc. è una società di biotecnologie in fase di sviluppo commerciale e fornisce farmaci mirati all'RNA negli Stati Uniti. L'azienda offre TRYNGOLZA, che riduce i livelli di trigliceridi negli adulti affetti da sindrome da chilomicronemia familiare (FCS) e pancreatite acuta; DAWNZERA, per la profilassi degli attacchi di angioedema ereditario negli adulti; WAINUA, per il trattamento della polineuropatia da amiloidosi ereditaria da transtiretina (ATTRv-PN) negli adulti; e SPINRAZA, per i pazienti pediatrici e adulti affetti da atrofia muscolare spinale (SMA). Inoltre, fornisce QALSODY per il trattamento della sclerosi laterale amiotrofica (SLA), TEGSEDI per il trattamento dell'ATTRv-PN negli adulti e WAYLIVRA per il trattamento della FCS e della lipodistrofia parziale familiare.
Ionis Pharmaceuticals, Inc. Riepilogo dei fondamenti
| IONS statistiche fondamentali | |
|---|---|
| Capitalizzazione di mercato | US$9.91b |
| Utili (TTM) | -US$565.17m |
| Ricavi(TTM) | US$874.09m |
11.6x
Rapporto P/S-17.9x
Rapporto P/EIONS è sopravvalutato?
Vedi Fair Value e analisi di valutazioneUtili e ricavi
| IONS Conto economico (TTM) | |
|---|---|
| Ricavi | US$874.09m |
| Costo del fatturato | US$934.70m |
| Profitto lordo | -US$60.60m |
| Altre spese | US$504.57m |
| Utili | -US$565.17m |
Ultimi utili riportati
Jun 30, 2026
Prossima data di guadagno
n/a
| Utile per azione (EPS) | -3.40 |
| Margine lordo | -6.93% |
| Margine di profitto netto | -64.66% |
| Rapporto debito/patrimonio netto | 438.1% |
Come si è comportato IONS nel lungo periodo?
Vedi performance storica e confrontoAnalisi aziendale e situazione dei dati finanziari
| Dati | Ultimo aggiornamento (ora UTC) |
|---|---|
| Analisi dell'azienda | 2026/08/19 16:58 |
| Prezzo dell'azione a fine giornata | 2026/08/19 00:00 |
| Utili | 2026/06/30 |
| Utili annuali | 2025/12/31 |
Fonti dei dati
I dati utilizzati nella nostra analisi aziendale provengono da S&P Global Market Intelligence LLC. I seguenti dati sono utilizzati nel nostro modello di analisi per generare questo report. I dati sono normalizzati, il che può comportare un ritardo nella disponibilità della fonte.
| Pacchetto | Dati | Tempistica | Esempio Fonte USA * |
|---|---|---|---|
| Dati finanziari della società | 10 anni |
| |
| Stime di consenso degli analisti | +3 anni |
|
|
| Prezzi di mercato | 30 anni |
| |
| Proprietà | 10 anni |
| |
| Gestione | 10 anni |
| |
| Sviluppi principali | 10 anni |
|
* Esempio per i titoli statunitensi, per i titoli non statunitensi si utilizzano forme e fonti normative equivalenti.
Se non specificato, tutti i dati finanziari si basano su un periodo annuale ma vengono aggiornati trimestralmente. Si tratta dei cosiddetti dati TTM (Trailing Twelve Month) o LTM (Last Twelve Month). Per saperne di più.
Modello di analisi e Snowflake
I dettagli del modello di analisi utilizzato per generare questo report sono disponibili sulla nostra pagina GitHub; abbiamo anche delle guide su come utilizzare i nostri report e dei tutorial su YouTube.
Scoprite il team di livello mondiale che ha progettato e realizzato il modello di analisi Simply Wall St.
Metriche di settore e industriali
Le nostre metriche di settore e di sezione sono calcolate ogni 6 ore da Simply Wall St; i dettagli del nostro processo sono disponibili su Github.
Fonti analitiche
Ionis Pharmaceuticals, Inc. è coperta da 44 analisti. 23 di questi analisti ha fornito le stime di fatturato o di utile utilizzate come input per il nostro report. Le stime degli analisti vengono aggiornate nel corso della giornata.
| Analista | Istituzione |
|---|---|
| James Birchenough | Barclays |
| Eliana Merle | Barclays |
| Huidong Wang | Barclays |